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Switching between anti-TNF-alpha agents does 
not improve functional capacity in patients with 
long-standing and active rheumatoid arthritis
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Karine R. Luz1, Rozana M. Ciconelli2, Marcelo M. Pinheiro3
ABSTRACT
Objectives: To assess clinical response after switching between anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents 
in patients with rheumatoid arthritis (RA). Patients and methods: This study included 99 patients diagnosed with RA 
(American College of Rheumatology, 1987), on anti-TNF-alpha therapy, to assess the therapeutic response after 24 weeks. 
Switching was performed if, after 12 to 24 weeks, a severe adverse event was reported (toxicity: T) or if no reduction greater 
than 0.6 in the initial Disease Activity Score 28 (DAS28) occurred (inadequate response: IR). In case of IR, the patient 
was considered as primary failure (PF). Secondary failure (SF) was deﬁ ned as loss of response after initial improvement. 
Remission (DAS28 < 2.6), low disease activity (between 2.61 and 3.2), and functional improvement [increase in the initial 
Health Assessment Questionnaire (HAQ) > 0.2] were assessed by use of linear regression analysis. The signiﬁ cance level 
adopted was P < 0.05. Results: Switching was performed in 39 (39.4%) patients, especially due to PF (24.3%), SF (35.1%) and 
T (40.5%). The retention rate of the ﬁ rst agent was 60.1%, and the mean time for switching was 14.2 ± 10.9 months. 
After switching, a tendency towards a decrease in DAS28 was observed (4.7 ± 1.4; P = 0.08), but not in the HAQ 
(1.2  ± 0.77; P = 0.11). Around 43% of the patients achieved good/moderate EULAR response. The major determinant 
of switching was a higher initial DAS28, independent of age, duration of disease, and functional capacity. Conclusion: 
Switching between anti-TNF-alpha agents is a valid strategy to control disease activity, despite the low likelihood of remis-
sion and no signiﬁ cant improvement in functional capacity.
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INTRODUCTION
In the past decade, the treatment of rheumatoid arthritis (RA) 
underwent great changes with the introduction of anti-tumor 
necrosis factor-alpha (anti-TNF-alpha) agents, and especially 
with the advances in clinical and radiographic control of the 
disease. However, some patients either do not respond, or 
respond only partially, to TNF-alpha inhibitors. In addition, pa-
tients who initially responded can experience either a decrease 
in the efﬁ cacy of TNF-alpha inhibitors over time, or adverse 
events, requiring new therapeutic strategies.
In Brazil, inﬂ iximab (IFX), etanercept (ETN), and adali-
mumab (ADA) are currently available, being usually associ-
ated with methotrexate (MTX) or other disease-modifying 
antirheumatic drugs (DMARDs), except when intolerance or 
toxicity occurs. Although anti-TNF-alpha agents have similar 
clinical efﬁ cacy and costs, they differ in the following aspects: 
molecular structure; pharmacokinetics; mechanism of action; 
potential to form autoantibodies, and human anti-chimeric 
(HACA) or human anti-human (HAHA) antibodies; induc-
tion of apoptosis; and posology.1–3 Thus, switching from one 
anti-TNF-alpha agent to another might be a treatment option 
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in patients experiencing loss of efﬁ cacy or intolerance to the 
ﬁ rst treatment.1,2
This study aimed at assessing the clinical response, especially 
functional capacity, after switching from one anti-TNF-alpha 
agent to another in patients with active, long-standing RA, and 
who had failed to respond to DMARDs, including MTX.
PATIENTS AND METHODS
From January 2004 to January 2010, a retrospective analysis 
of the database of patients followed up at the Outpatient 
Clinic of Rheumatoid Arthritis and Biologics of the 
Discipline of Rheumatology of Escola Paulista de Medicina, 
Universidade Federal de São Paulo (EPM/UNIFESP), was 
carried out. All patients diagnosed with RA, according to 
the American College of Rheumatology 1987 classiﬁ cation 
criteria,4 and on anti-TNF-alpha therapy5 were included in 
the study.
Approximately 1,300 patients diagnosed with RA are an-
nually followed up at that service, and 99 of them (7.6%) met 
the inclusion criteria of this study. Of those 99 patients, 39 
(39%) underwent switching of the anti-TNF-alpha agent during 
follow-up, and were included in this analysis.
The non-inclusion criterion adopted was lack of data (initial 
and after six months). In addition, patients with the following 
characteristics were excluded: global functional status class 
IV;6 inability to answer the questionnaires; other autoimmune 
rheumatic diseases; neoplasias; and other disabling diseases. 
From this cohort, only two patients were excluded, due to lack 
of follow-up data after switching.
The reasons for discontinuing the ﬁ rst anti-TNF-alpha 
agent were classiﬁ ed as follows: primary failure (PF); second-
ary failure (SF); adverse event (AE); and consent withdrawal 
(personal reasons, travel, loss to follow-up). Primary failure 
was deﬁ ned as a DAS28 (Disease Activity Score 28) reduc-
tion lower than 0.6 after 12 weeks [no EULAR (EUropean 
League Against Rheumatism) response]. Secondary failure 
was deﬁ ned as loss of efﬁ cacy (a DAS28 increase over 
0.6 from the initial value) over 24 weeks in patients who had 
responded in the ﬁ rst 12 weeks, based on a DAS28 reduction 
greater than 0.6.7
Adverse event was deﬁ ned as any medical occurrence not 
initially predicted, which appeared after switching the anti-
TNF-alpha therapy. Severe AE was deﬁ ned as any medical 
occurrence not initially predicted and that resulted in death, 
caused danger of death, or required or extended the ongoing 
hospitalization. Such events might, but not necessarily, have 
causal relation to the research procedures.8
Clinical and laboratory assessments included DAS28, 
erythrocyte sedimentation rate (ESR), and the Brazilian modi-
ﬁ ed version of the Health Assessment Questionnaire (HAQ).9,10 
All measures were performed before treatment and three and 
six months after. Response to therapy was assessed accord-
ing to both the DAS28 reduction and the criteria proposed by 
EULAR7 (no response: a reduction lower than 0.6 between two 
consecutive measures; moderate: a reduction between 0.6 and 
1.2; good: a reduction greater than 1.2). Clinical remission 
was deﬁ ned as a DAS28 lower than 2.6.10 Demographic data 
and disease characteristics were also included in the analysis. 
The synthetic DMARDs being used at the time of switching 
anti-TNF-alpha agents were not modiﬁ ed until the end of the 
reassessment (after 24 weeks), including stable dose and type 
of association.
The major risk factors associated with discontinuation were 
assessed by use of univariate linear regression and logistic 
regression. Three models were built, having the following 
dependent variables: HAQ (reduction of at least 0.2) in the 
ﬁ rst; moderate/good EULAR response (reduction greater than 
0.6) in the second; and remission (DAS28 < 2.6) in the third. 
All other variables were considered as independent. For the 
statistical analysis, the SPSS (Statistical Package for Social 
Science) software, version 15.0, was used. The signiﬁ cance 
level adopted was P < 0.05. 
RESULTS
At the end of the study, 37 patients were analyzed. Their 
mean age was 52 years, and the female gender predomi-
nated (89.3%). Most patients had long-standing and erosive 
disease, as well as high positivity for rheumatoid factor and 
impaired functional capacity (Steinbrocker functional class 
II and III)6 (Table 1).
Table 1
Clinical and demographic characteristics of 37 patients with 
RA undergoing switching to a second anti-TNF-alpha agent
Age (years) 51.6 ± 11.7
Female gender (%) 33 (89.3%)
Duration of disease (months) 181.4 ± 96.4
ACR functional class
I 3 (8.1%)
II 21 (56.8%)
III 13 (35.1%)
Positive rheumatoid factor 29 (78.4%)
Erosion on radiography (hands or feet) 31 (83.8%)
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Similarly, most patients were using prednisone, at a mean 
daily dose of almost 10 mg. Almost 50% of the patients were 
using MTX in combination with TNF-alpha inhibitors, at a 
mean weekly dose close to 25 mg. In addition, slightly more 
than 80% of the patients were using leﬂ unomide (LFN) in as-
sociation with anti-TNF-alpha agents. Of those, 21.6% were 
on an association of LFN and MTX (Table 2).
Before using the ﬁ rst anti-TNF-alpha agent, almost 20% of 
the patients received isoniazid for treating latent tuberculous 
infection (LTBI), as recommended by the Brazilian Society of 
Rheumatology.5 None of them had any signiﬁ cant AE that could 
determine the switching of any medication. Of the 39 patients 
undergoing switching between anti-TNF-alpha agents, none used 
isoniazid again, since no reinvestigation for LTBI was conducted 
prior to the introduction of the second TNF-alpha inhibitor. Thus, 
no association was observed between the use of isoniazid, either 
in the ﬁ rst or second time, and the AEs causing the switching 
between agents. However, for one patient, the switching strategy 
was used due to professional epidemiology (the patient is a com-
munity health agent of the Family Health Program).
The most frequently used ﬁ rst anti-TNF-alpha agent was 
IFX, followed by ETN and ADA at the same proportion (Table 2). 
However, most patients (69.6%) required an IFX dose increase 
or infusion interval reduction, to maintain the clinical beneﬁ t 
over time. The mean length of use of the ﬁ rst anti-TNF-alpha 
agent, prior to switching, was 14.6 ± 10.7 months. In that pe-
riod, a signiﬁ cant decrease in DAS28 and an improvement in 
the functional capacity were observed (Table 3).
Switching between monoclonal antibodies occurred in 43.2% 
of the patients. In almost 40% (n = 14) of the sample, switching 
was from monoclonal antibodies (IFX or ADA) to soluble TNF-
alpha receptor (ETN). Seven patients (18.9%) switched from 
the soluble receptor to monoclonal antibodies. Thus, as second 
anti-TNF-alpha agent, 21 patients (56.8%) used ADA, 14 (37.8%) 
used ETN, and only two (5.4%) used IFX (Figure 1).
Table 2
Frequency of use of DMARDs and anti-TNF-alpha agents in 
37 patients with RA on immunobiologic therapy
Daily dose of prednisone (mg) 9.5 ± 8.6
Weekly dose of methotrexate (mg) 23 ± 3.8
DMARDs
Methotrexate 17 (46.8%)
Leﬂ unomide 22 (59.5%)
Methotrexate + leﬂ unomide   8 (21.6%)
First anti-TNF-alpha agent
Inﬂ iximab 23 (62.2%)
Adalimumab   7 (18.9%)
Etanercept   7 (18.9%)
Second anti-TNF-alpha agent
Inﬂ iximab   2 (5.4%)
Adalimumab 21 (56.8%)
Etanercept 14 (37.8%)
Table 3
Clinical and laboratory assessment before and after switching 
between anti-TNF-alpha agents 
ESR (mm/1a h) DAS28 HAQ
First anti-TNF-alpha
Before 35.5 ± 20.8 5.7 ± 1.2 1.2 ± 0.5
After 29.6 ± 19.5 4.6 ± 1.4 0.97 ± 0.6
P* 0.1 0.004 0.02
Second anti-TNF-alpha
Before 36.4 ± 26.8 5.2 ± 1.3 1.4 ± 0.7
After 36.2 ± 24.2 4.7 ± 1.4 1.2 ± 0.7
P** 0.9 0.08 0.1
*Statistical difference between beginning and end of the ﬁ rst anti-TNF-alpha agent (Student t test). 
**Statistical difference between beginning and end of the second anti-TNF-alpha agent (Student t test).
Figure 1
Switching strategy between anti-TNF-alpha agents.
Switching strategy between 
anti-TNF agents
From monoclonal to
monoclonal (43.2%)
From monoclonal 
to receptor (37.9%)
From receptor to 
monoclonal (18.9%)
Regarding the reasons for switching the ﬁ rst anti-TNF-alpha 
agent, nine patients (24.3%) had PF, 13 (35.2%) had SF, and 15 
(40.5%) had AE. The major AEs motivating the switch were 
as follows: infusion reaction (n = 4); urticaria (n = 7); respira-
tory infection (n = 1); and other causes (n = 3), such as upper 
gastrointestinal hemorrhage and strong epidemiology for LTBI 
(professional contact with bacillus-carrying patients) (Figure 2). 
Among those switching agents due to AEs, the mean length of 
use of the ﬁ rst anti-TNF-alpha agent was 9.3 ± 6.9 months, and 
the mean DAS28 before and after the ﬁ rst anti-TNF-alpha agent 
were 5.9 ± 1.2 and 4.6 ± 1.1, respectively. More than half of them 
(54.5%) had achieved a good EULAR response, while 18.2% 
obtained a moderate response, and 27.3% no response. In the ﬁ rst 
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24 weeks after switching, no relevant AE was observed, even in 
those patients who had switched due to toxicity to the ﬁ rst agent.
After switching to the second anti-TNF-alpha agent, disease 
activity tended to improve, but at a lower magnitude than that 
of the ﬁ rst agent, according to the reduction in DAS28, but 
not in functional capacity (Table 3). However, using the deﬁ ni-
tion of the EULAR response, 43.6% (n = 17) of the patients 
achieved good to moderate response after the introduction of 
the second anti-TNF-alpha agent, although only two (5.4%) 
went into clinical remission. In isolation, ESR was not a good 
parameter to assess the short-term laboratory response.
Only two (5.4%) patients switched the class of medication 
after using the second anti-TNF-alpha agent. For both, ritux-
imab was used due to PF. None of the patients used a third 
anti-TNF-alpha agent.
After 24 weeks, when classifying patients according to 
the ﬁ nal DAS28 into low, and moderate/high activity, the ﬁ rst 
group had a signiﬁ cantly lower HAQ than that of the second 
group (Table 4), and also received lower doses of glucocorti-
coids (GC) and MTX, regardless of age, duration of disease, 
presence of rheumatoid factor, and erosions on radiography. 
Such aspects might characterize disease with better outcome 
and prognosis (P < 0.05).
On univariate linear analysis, age, duration of disease, and 
erosive disease did not signiﬁ cantly inﬂ uence the clinical response 
to the second anti-TNF-alpha agent. In the ﬁ nal model of logistic 
regression for low disease activity (DAS28 between 2.61 and 
3.2) and good/moderate EULAR response, none of the variables 
studied were signiﬁ cant enough to explain patients’ improvement, 
except for a tendency towards the lowest value of the initial DAS 
(OR = 0.15; 95% CI: 0.02–1.26; P = 0.08). Thus, for each unit 
increase in the initial DAS28, there was a 85% reduction in the 
chance of having low disease activity after switching the anti-TNF-
alpha agent, even after statistical adjustments for age, duration 
of disease, rheumatoid factor, initial HAQ, erosions, prednisone, 
MTX, anti-TNF-alpha agent, or reason for switching. The ﬁ nal 
logistic regression model for remission (DAS28 < 2.6) was not 
performed, because of the small number of patients.
DISCUSSION
Our results showed that the switching strategy between anti-
TNF-alpha agents was performed in 39% of the patients. That 
frequency is slightly higher than that reported by other authors, 
mainly those data originating from studies of registries, in 
which 25%–40% of the patients discontinue treatment in 
the ﬁ rst 12 months due to loss of efﬁ cacy or AEs.1–3,11–13 It is 
worth emphasizing that the long duration of disease and the 
high prevalence of individuals with erosive disease, although 
with moderate physical incapacity, characterized this cohort. 
Such aspects can explain the higher prevalence of that strategy.
Usually, some aspects should be considered for decision 
making and choosing the first or second anti-TNF-alpha 
agent (Chart 1). Several causes can justify switching between 
Table 4
Clinical and laboratory characteristics of the groups with low 
and moderate/high disease activity, according to ﬁ nal DAS28, 
after switching between anti-TNF-alpha agents 
DAS28 < 3.2 DAS28 > 3.21 P
Age (years) 52.8 ± 9.6 51.2 ± 12.3 0.81*
Initial DAS28 3.89 ± 0.57 5.48 ± 1.19 0.017*
Initial HAQ 1.04 ± 0.73 1.38 ± 0.75 0.046*
Prednisone (mg/day) 4.3 ± 9.5 9.7 ± 8.7 0.036*
Methotrexate (mg/week) 13.4 ± 5.8 21.3 ± 4.6 0.029*
Rheumatoid factor 72.4% 73.7% 0.95**
Presence of erosions on 
radiography (baseline)
89.2% 85.7% 0.99**
*Student t test. ** Fisher exact test.
Chart 1
Aspects considered for decision making and choice of anti-
TNF-alpha therapy
Patient’s adhesion Patient’s and physician’s opinion 
Patient’s cognitive aspects Convenience of application
Posology and pharmacological 
properties (for example, plas-
ma and tissue half-lives)
Administration route 
(intravenous or subcutaneous)
Need for combined therapy with MTX 
or other DMARDs versus monotherapy
Potential risk of repeated 
or granulomatous infection 
(tuberculosis, leprosy, 
schistosomiasis)
Associated diseases, including other 
rheumatic diseases concomitant with 
RA: Sjögren’s syndrome, systemic lupus 
erythematosus, systemic sclerosis, 
inﬂ ammatory myopathies, vasculites
Involvement of other organs 
or systems: ocular, hepatic, 
intestinal, pulmonary, 
cardiac, nervous, vascular
Figure 2
Reasons for switching between anti-TNF-alpha agents.
Reasons for switching 
between anti-TNF-alpha 
agents (n = 37)
Primary failure 
n = 9 (24.3%) 
Secondary failure 
n = 13 (35.2%)
Adverse events 
n = 15 (40.5%)
 
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anti-TNF-alpha agents of the same class or with a similar 
mechanism of action; however, usually the failure in respond-
ing (PF or SF) and the AEs are the major causes in most clinical 
studies published.1,2
Similarly to the present study, Marchesoni et al.,13 in a large 
cohort of patients on anti-TNF-alpha therapy, have reported 
that of the 1,064 individuals assessed, 38.1% discontinued the 
medication. Of those, 44.4% discontinued due to inefﬁ cacy, 
47.9% due to AEs, and 2.5% due to disease remission. After 
36 months, ETN had the best drug survival rate (62.5%) as 
compared with IFX (49.1%) and ADA (53.2%). The greatest 
risk of discontinuing therapy due to some AE was associated 
with advanced age and current use of GC; while the loss of 
efﬁ cacy was associated with previous use of more than three 
DMARDs and higher ESR.13
In 40.5% of our patients, the reason for switching the anti-
TNF-alpha agent was the presence of an AE. Usually, high 
retention rate of the second anti-TNF-alpha agent is observed 
in the ﬁ rst year (50%–70%), and switching from one anti-TNF-
alpha agent to another can elicit an adequate clinical response, 
especially if caused by toxicity, as shown in a recent systematic 
review that assessed approximately six thousand patients.3 A 
similar ﬁ nding has already been reported by Hyrich et al.,12 
who, assessing patients switching the ﬁ rst anti-TNF-alpha 
agent (503 due to inefﬁ cacy and 353 due to toxicity), have 
shown high response and maintenance rates with the second 
anti-TNF-alpha agent (73%), especially when the switch was 
motivated by toxicity.12 Of our 15 patients (40.5%) having AEs, 
ﬁ ve (33%) obtained a good/moderate EULAR response after 
the switch. Six (27.2%) of those discontinuing the use of the 
ﬁ rst anti-TNF-alpha agent due to inadequate response (59.5%) 
had good/moderate EULAR response. Thus, according to such 
data, clinical response to the second anti-TNF-alpha agent 
did not depend on the reason for switching (mean of 30%). In 
addition, toxicity of the second agent was not observed in the 
ﬁ rst 24 weeks, even in patients with severe AEs resulting from 
the ﬁ rst anti-TNF-alpha agent. It is worth emphasizing once 
more that anti-TNF-alpha agents are different, and switching 
between them is an important strategy in the clinical manage-
ment of those patients.
Compared to ours, Navarro-Sarabia et al.14 have reported 
a lower rate of switching to the second anti-TNF-alpha agent 
(19.9%), but similar frequency of good/moderate EULAR 
response (47%) and reasons for switching. Almost half of their 
patients assessed showed improvement of the HAQ (over 0.22) 
with the second anti-TNF-alpha agent,14 while only 35% of 
our sample achieved that response. Caporali et al.,15 assessing 
the data of the Italian registry of the anti-TNF-alpha agents, 
have also reported a lower switching rate (21.3%) than ours, 
especially due to PF (36.3%). Slightly more than 47% have 
achieved a good/moderate EULAR response after six months, 
and 58.6% after 12 months. Patients with high disease activity 
and those switching due to loss of efﬁ cacy had a greater chance 
to respond to the second agent.15
Almost 45% of our patients switched between monoclonal 
antibodies, a strategy less used than that including the soluble 
TNF-alpha receptor. Burmester et al.16 have shown a high rate 
of good clinical response after 12 weeks in 358 patients who 
had switched from IFX to ADA, with 20% improvement in the 
American College of Rheumatology criteria (ACR20) in 63% 
of the patients, and 50/70% improvement in the ACR criteria 
(ACR50/70) in 35% and 12%, respectively.16 For a longer time 
(six months), but with a smaller number of patients (n = 27), 
Wick et al.17 have reported a similar response with the same 
strategy of switching between anti-TNF-alpha agents, shown 
as a signiﬁ cant reduction in DAS28 values and proportion of 
individuals achieving ACR20, even when compared with a 
third group of ADA-naïve.17 A similar study with similar ﬁ nd-
ings, during 12 months, has been published by Nikas et al.18 
and Van der Bijl et al.19
Switching from monoclonal antibodies to the soluble TNF-
alpha receptor was performed in 37.8% of our patients. The 
clinical response, according to the ACR criteria, has been stud-
ied by Haraoui et al.20 in patients with RA who had switched 
from IFX to ETN due to lack of efﬁ cacy or AE. ACR20/50/70 
response was observed in 64%, 23%, and 5% of the patients, 
respectively.20 Buch et al.21 have switched from IFX to ETN, 
and, after 12 weeks, they have reported good/moderate EULAR 
response in 73% of the patients. It is worth noting that none 
of the patients who had discontinued IFX due to toxicity ex-
perienced AEs due to ETN.21 Similar ﬁ ndings have also been 
reported by other authors.22–24
Almost 20% of our patients switched from the soluble TNF-
alpha receptor to monoclonal antibodies. Regarding the switch 
from the soluble TNF-alpha receptor to monoclonal antibodies, 
Gomes-Reino et al.,11 assessing data from the Spanish registry, 
have reported that 52 patients on ETN switched to IFX, and 14 
to ADA. After 12 months, those authors have found a higher 
drug continuity rate with the same agent in those patients who 
had switched to ADA (75%) as compared with those who 
had switched to IFX (28%, of whom 54% discontinued due 
to AEs).11 Wick et al.17 have studied switching from ETN to 
ADA, with a signiﬁ cant reduction in the DAS28. With the same 
strategy and a larger sample, but with only three months of 
follow-up, Burmester et al.16 have observed the ACR20/50/70 
response at the proportion of 52/30/11, respectively. Scrivo et 
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al.2 have also assessed the response to ADA of patients who had 
used ETN. After three months, 64% of the patients showed an 
adequate EULAR response, but almost 40% failed to respond.2 
Although with few patients, Furst et al.,25 van Vollenhoven et 
al.,26 Hansen et al.,27 and Cohen et al.28 have reported similar 
ﬁ ndings.
The major risk factors associated with switching between 
anti-TNF-alpha agents are the traditional risk factors of worse 
prognosis, such as poor response to DMARDs, greater number 
of swollen joints, longer disease duration, greater degree of 
disability, and persistently elevated inﬂ ammatory activity tests. 
Although the literature is still controversial, the presence of 
HACAs or HAHAs seems to be related to immuno-allergic and 
infusion reactions rather than to loss of efﬁ cacy.29 In our study, 
only the higher disease activity, measured by DAS28, associ-
ated with worse clinical response after the switching strategy, 
independently of disease duration, age, physical disability, 
rheumatoid factor, and erosions on radiography.
More recently, Rémy et al.,30 in a systematic review of the 
literature with subsequent meta-analysis of 32 relevant stud-
ies and inclusion of 4,441 patients, have shown good clinical 
relevance of the switching strategy between anti-TNF-alpha 
agents. ACR20 and EULAR responses were observed in 
55.1% and 74.9% of the patients, respectively, a ﬁ nding very 
similar to those of pivotal studies with anti-TNF-alpha-naïve 
individuals. Once again, the authors have conﬁ rmed previous 
results, in which switching due to inadequate response was 
associated with lower ACR20 response (54.3%) vs. switching 
due to AEs (62,5%). However, no signiﬁ cant difference was 
observed when that outcome was statistically assessed by use 
of EULAR response.30
Most published studies on the switching strategy to the 
second anti-TNF-alpha agent have assessed parameters related 
to improvement in clinical activity,12,15–17,20,21,31 but not to other 
outcomes, such as the functional ones, remission, quality of 
life, and structural damage on radiography. This study, how-
ever, assesses functional capacity and remission as primary 
outcomes. Considering the new remission criteria recently 
proposed by ACR/EULAR [SDAI ≤ 3.3, or tender and swol-
len joint counts, patient’s global assessment, and C-reactive 
protein ≤ 1],32 none of our patients would meet these criteria.
Our study has some limitations, such as the retrospective 
design and its inherent problems, and the relatively reduced 
number of patients in each subgroup, after stratifying ac-
cording to the reason for switching. Therefore, assessing 
the response effectiveness in each clinical setting was not 
possible. However, our study has some strong points, such 
as the low loss to follow-up rate and the functional capacity 
assessment, an outcome rarely reported in most studies. It 
is worth noting that, although patients had a long disease 
duration, they had moderate physical disability (mean HAQ 
< 1.5, and functional class II and III), which neither causes 
selection bias nor hinders the ﬁ nding. Moreover, it draws 
attention to the greater weekly dose of MTX and greater 
frequency of leﬂ unomide users, differently from that reported 
in the international literature.3,11,26,33 The lack of bias of con-
comitant medication strengthens the role of immunobiologic 
agents, since the doses and type of combination of synthetic 
DMARCs were maintained stable for 24 weeks after switch-
ing between anti-TNF-alpha agents.
Thus, our data suggest that switching between anti-TNF-
alpha agents is a valid strategy for the clinical management of 
patients with RA, particularly using the improvement criteria 
proposed by EULAR, although with low probability of remis-
sion and no signiﬁ cant improvement in functional capacity. 
However, further clinical studies, especially prospective, 
randomized and controlled ones, and with larger samples, are 
required to deﬁ ne the best way to manage those patients. Such 
studies should include the demonstration of structural beneﬁ t, 
gain in quality of life, and missed work days.
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